| Summary: | 碩士 === 中國醫藥學院 === 中國醫藥研究所 === 86 === Ethylphenylacetamide (EPA) was a new compound with antitumoral and
antiproliferative effects on Colo 205, T-24, and HL-60 cell lines.
Phenylacetic acid (PA) was the parent compound of EPA, but its clinical
use was limited by the objectionable odor and high polarity. EPA could
overcome these defects.
EPA was used to determined inhibition of cell growth by trypan blue
exclusion and revealed it suppressed the proliferation in three examined
human malignant cell lines. EPA also induced differentiation of HL-60
cells and appeared changes in morphology. The DNA content analysis was
determined by FACS. EPA treatment of Colo205, T-24, HL-60 cultures
resulted in the inhibition of S phase in cell cycle. The proportion of cells in
S phase progressive deceased concomitant with an increase in G1 phase
cells. After 6 hr, EPA treatment at 1.0 mM of Colo 205 cells obtained the
obvious inhibition in S phase. T-24 and HL-60 cells changed their cell
cycle distribution in response to EPA after 12 and 24 hr. After 24 hr
treatment with EPA, apoptosis in the form of subdiploid peak became
evident. The degradation of genomic DNA was also analyzed in response
to EPA treatment by size fraction in Colo 205, T-24, and HL-60 cell lines.
EPA could degraded the DNA of these cells results in the DNA damage.
The results indicated that EPA decreased N-acetyltransferase activity in rat
tissues and human tumor cell lines. Above these, EPA was found to affect
the growth and differentiation of tumor cell lines and demonstrated that it
was a new promising anticancer drug.
|
|---|
